EUVIMEDEUVIMED entdecken
Crossref

A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy

Zenghui Li iD, Yuqing Feng, Hong Han, Xingyue Jiang, Weiyu Chen, Xuezhen Ma, Yang Mei, Dan Yuan, Dingxiao Zhang, Junfeng Shi iD

Angewandte Chemie International Edition · 2024

DOI: 10.1002/anie.202402611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Zenghui Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Key Laboratory of Animal Models and Molecular Medicine, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, School of Biomed…. Hauptthemen laut MEDLINE: Methyltransferases, Peptides, Antineoplastic Agents. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science Fund for Distinguished Young Scholars of Hunan Province, Postgraduate Scientific Research Innovation Project of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

METTL3, a primary methyltransferase catalyzing the RNA N6‐methyladenosine (m6A) modification, has been identified as an oncogene in several cancer types and thus nominated as a potentially effective target for therapeutic inhibition. However, current options using this strategy are limited. In this study, we targeted protein–protein interactions at the METTL3–METTL14 binding interface to inhibit complex formation and subsequent catalysis of the RNA m6A modification. Among candidate peptides, RM3 exhibited the highest anti‐cancer potency, inhibiting METTL3 activity while also facilitating its proteasomal degradation. We then designed a stapled peptide inhibitor ( RSM3 ) with enhanced peptide stability and formation of the α‐helical secondary structure required for METTL3 interaction. Functional and transcriptomic analysis in vivo indicated that RSM3 induced upregulation of programmed cell death‐related genes while inhibiting cancer‐promoting signals. Furthermore, tumor growth was significantly suppressed while apoptosis was enhanced upon RSM3 treatment, accompanied by increased METTL3 degradation, and reduced global RNA methylation levels in two in vivo tumor models. This peptide inhibitor thus exploits a mechanism distinct from other small‐molecule competitive inhibitors to inhibit oncogenic METTL3 activity. Our findings collectively highlight the potential of targeting METTL3 in cancer therapies through peptide‐based inhibition of complex formation and proteolytic degradation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethyltransferasesPeptidesAntineoplastic AgentsHumansAdenosineAnimalsCell ProliferationMiceNeoplasmsEnzyme InhibitorsCell Line, TumorApoptosis

Stichwörter der Autor:innen

CancerInhibitorMETTL3PeptideStapling

Substanzen

MethyltransferasesMETTL3 protein, humanPeptidesMETTL14 protein, humanAntineoplastic AgentsAdenosineEnzyme Inhibitors

Autor:innen und Institutionen

  • Hunan Provincial Key Laboratory of Animal Models and Molecular Medicine, State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, School of Biomedical Sciences, Hunan University Changsha, Hunan, 410082, China.
  • Greater Bay Area Institute for Innovation Institution, Guangzhou, 511300, Guangdong Province, China.
  • Shenzhen Research Institute, Hunan University, Shenzhen, 518000, Guangdong Province, China.

ORCID-Profile: Zenghui Li, Junfeng Shi

Förderung

  • National Natural Science Foundation of China
  • Science Fund for Distinguished Young Scholars of Hunan Province
  • Postgraduate Scientific Research Innovation Project of Hunan Province

Zitieren

APA

Li, Z., Feng, Y., Han, H., Jiang, X., Chen, W., Ma, X., Mei, Y., Yuan, D., Zhang, D., & Shi, J. (2024). A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202402611

Vancouver

Li Z, Feng Y, Han H, Jiang X, Chen W, Ma X, et al. A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202402611

BibTeX
@article{Li2024,
  author = {Li, Zenghui and Feng, Yuqing and Han, Hong and Jiang, Xingyue and Chen, Weiyu and Ma, Xuezhen and Mei, Yang and Yuan, Dan and Zhang, Dingxiao and Shi, Junfeng},
  title = {A Stapled Peptide Inhibitor Targeting the Binding Interface of N6‐Adenosine‐Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy},
  journal = {Angewandte Chemie International Edition},
  year = {2024},
  doi = {10.1002/anie.202402611}
}
Kostenlos starten →